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Abstract: The treatment of symptomatic aortoiliac occlusive disease has shifted from open to 
endovascular repair. Both short- and long-term outcomes after percutaneous angioplasty and 
stenting rival those after open repair and justify an endovascular-first approach. In this article, 
we review the current endovascular treatment strategies in patients with aortoiliac occlusive 
disease, indications for primary and selective stenting in the iliac artery, and physical properties 
and future perspectives of self-expanding stents.
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Introduction
The prevalence of peripheral arterial disease (PAD) in the US is more than 4% 
among adults aged 40 years and over. PAD increases dramatically with age and the 
prevalence exceeds 14% among those aged 70 years or over.1 One subset of PAD is 
aortoiliac occlusive disease (AIOD), defined as any stenosis or occlusion from the 
distal aorta to the common femoral artery (CFA). Conventional surgical revascular-
ization of AIOD is associated with excellent long-term patency rates.2,3 However, 
open repair is also associated with a significantly longer hospital stay and higher 
complication rates and inpatient costs, compared with endovascular treatment.4 The 
TransAtlantic Intersociety Consensus (TASC) II, published in 2007, recommends 
endovascular therapy for straightforward AIOD (TASC A lesions) and surgery 
for complex AIOD (TASC D lesions).5 However, due to the rapid development of 
endovascular techniques and improved competence, experienced centers advocate an 
“endovascular first” approach. In recent years, endovascular treatment has become 
widespread and is the preferred method of treatment nowadays for lower extremity 
arterial obstructions.6
Endovascular treatment of AIOD consists of percutaneous transluminal angioplasty 
(PTA) with or without stenting. In a meta-analysis of six PTA studies (1,300 patients) 
and eight PTA and stent studies (816 patients), additional stenting was associated 
with an increased technical success rate and improved long-term patency.7 The results 
of endovascular treatment of AIOD have been described in multiple publications. 
Technical success and both short- and long-term patency rates have been satisfactory, 
even in challenging lesions.8,9 These results justify an endovascular-first approach for 
symptomatic AIOD treatment.





Overview of current endovascular 
treatment for AIOD
Primary versus selective stenting
The Dutch Iliac Stent Trial enrolled 279 patients with 
 intermittent claudication on the basis of iliac artery stenosis 
of .50%. The study randomly assigned 143 patients to direct 
stent placement (group I) and 136 to primary angioplasty, 
with selective stent placement in case of a residual mean 
pressure gradient .10 mmHg across the treated lesion 
(group II). The primary endpoint was clinical success, defined 
as improvement of at least one clinical category in the  Fontaine 
 classification.5 In group II, stents were selectively placed in 
43% of the patients. Less than 10% of patients were treated 
for iliac artery occlusions and the stenosis length was ,2 cm 
in 56% patients. Most lesions corresponded to TASC A and B 
lesions. Clinical success, cumulative patency, and reinterven-
tion rates at 2 years were similar between the groups.10 Long-
term results (after 5–8 years) showed a better clinical outcome 
in patients with PTA and selective stenting in the iliac artery. 
Iliac patency, ankle–brachial index, and quality of life did not 
support a difference between groups.11
More recent studies showed that primary stenting has 
significant benefits over angioplasty alone in TASC C and D 
aortoiliac lesions. In a nonrandomized series of 151 patients 
with iliac stenosis, a total of 110 consecutive patients 
(149 lesions) underwent primary stenting. The results were 
compared with 41 patients (41 lesions) who had PTA fol-
lowed by selective stenting for suboptimal PTA. The overall 
early clinical success rate was superior for the primary stent 
group (Figure 1). For TASC A and B lesions, the initial and 
late clinical success rates were comparable but were inferior 
in selective stenting for TASC C and D lesions.12
A recent meta-analysis of 16 reports including 958 patients 
with endovascular treatment of TASC C and D aortoiliac arte-
rial lesions found better patency rates for primary stenting 
than for selective stenting.8
The Stents Versus Angioplasty for the Treatment of Iliac 
Artery Occlusions (STAG) trial randomly assigned 112 patients 
with an iliac occlusion to PTA or primary stent placement. 
PTA was performed in 55 patients and primary stenting in 57. 
Technical success in the primary stenting group was higher 
(98% vs 84%) and major complications (predominantly distal 
embolization) occurred less frequently (5% vs 20%) compared 
with PTA. Patency rates did not differ after 1 and 2 years.13
Predictors of success or failure
Independent predictors of iliac endovascular intervention suc-
cess or failure have been described in multiple  publications. 
The presence of two-vessel femoral runoff or at least two 
patent below-the-knee vessels, or both, is associated with 
improved iliac artery primary patency.14 Poor outflow 
requiring a bypass is associated with decreased iliac artery 
primary patency rates.3 In another study, iliac PTA and 
stenting, combined with an untreated superficial femoral 
artery stenosis .50% resulted in a decreased primary pat-
ency rate.15
The presence of an iliac artery occlusion is considered an 
independent risk factor for patency loss.16 However, similar 
results after treatment of iliac stenoses and occlusions have been 
published. In a series of 73 patients including 76 occluded iliac 
arteries (33 common, 34 external, and nine both) the primary 
patency was 79% at 1 year and 69% at 3 years.17 In a prospec-
tive series of 223 patients with AIOD, endovascular treatment 
was performed for iliac occlusion in 109 patients and for iliac 
stenosis in 114 patients. No differences were observed in the 
complication rate or in short- and long-term patency rates.18
Other predictors for decreased primary patency include 
diabetes mellitus,3 age ,50 years,16 TASC C and D 
lesions,19,20 hypertension,14 hypercholesterolemia,14 chronic 
renal insufficiency,14 external iliac artery (EIA) disease,21 
female sex,21 and smoking history.19
Differences between the common  
and external iliac artery
The iliac artery is subdivided as the common, external, and 
internal iliac or hypogastric artery. Most publications describe 
results after iliac artery stenting and do not differentiate 
between the common iliac artery (CIA) and EIA (Table 1). 
This may be the result of the TASC II  classification.5 The 
TASC II classification defines aortoiliac lesions, potentially 
involving the distal aorta, CIA, EIA, and CFA. The limita-
tions of this rather generic aortoiliac TASC II classification 
have been described previously.22 We believe that in trials 
investigating stents in the iliac arteries, a distinction must be 
made between the straight and relative immobile CIA and 
the tortuous and mobile EIA. Subgroups should be created 
according to the anatomic characteristics of the target lesion 
rather than by the TASC II classification.23
One of the rare studies comparing stents in the CIA and 
EIA showed no differences in primary patency after 1, 2, and 
3 years.24 Two other studies, however, found EIA stenting was 
an independent predictor of decreased primary patency after 
iliac artery PTA and stenting.21,25 A more recent study evaluat-
ing a particular self-expandable stent showed no significant 
difference in the patency rates at 2 years among stents placed 
in the CIA, the EIA, and both the CIA and EIA.26




Self-expanding stents and aortoiliac occlusive disease
Table 1 An overview of recent studies presenting primary patency rates of percutaneous angioplasty and bare-metal balloon-
expandable (BE) or self-expandable (SE) stent placement in the iliac artery
Author Year of  
publication
Number  
of stented  
lesions
Type of  
stents





patency rate  
at 1 year
Primary  





Yilmaz et al16 2006 68 BE + SE CiA A, B, C 76% 63% 63%
Balzer et al27 2006 89 BE + SE CiA + EiA C, D NA 89.9% NA
Leville et al28 2006 92 BE + SE CiA + EiA B, C, D NA 76% NA
De Roeck et al29 2006 38 BE + SE CiA + EiA B, C, D 94% 89% 77%
AbuRahma et al12 2007 149 SE CiA + EiA A, B, C, D 98% 87% 77%
Carreira et al30 2008 31 SE CiA + EiA NA NA 83% 75%
Gandini et al31 2008 138 BE + SE CiA + EiA NA NA 90% 85%
Sixt et al32 2008 354 BE + SE CiA + EiA A, B, C, D NA NA NA
Kashyap et al3 2008 127 BE + SE CiA + EiA B, C, D NA 74% NA
Higashiura et al33 2009 216 SE CiA + EiA A, B, C, D NA 93% 91%
Koizumi et al34 2009 296 BE + SE CiA + EiA A, B, C, D NA 88% 82%
Maurel et al35 2009 90 BE + SE EiA A, B, C, D 97% 84% NA
Ozkan et al20 2010 127 BE + SE CiA + EiA B, C, D NA NA 63%
Jaff et al26 2010 151 SE CiA + EiA NA NA 91%  
(at 2 years)
NA
ichihashi et al36 2011 533 BE + SE CiA + EiA A, B, C, D 90% 88% 83%
Soga et al37 2012 2,601 BE + SE CiA + EiA A, B, C, D 92.5% 82.6% 77.5%
Kordecki et al38 2012 95 SE CiA + EiA A, B, C, D 84% 76%  
(at 2 years)
NA
Bosiers et al39 2013 147 SE* CiA + EiA A, B, C, D 93.1% NA NA
Araki et al40 2013 86 SE CiA + EiA B, C, D NA 96.5%  
(at 2 years)
NA
Note: *For publications considering both BE and SE stents, only data of SE stents were displayed, if available.
Abbreviations: CIA, common iliac artery; EIA, external iliac artery; NA, not available; TASC, TransAtlantic Intersociety Consensus.
Self-expanding stents and AIOD
Self-expanding stent
Most self-expanding stents are made of nitinol, an alloy of 
nickel and titanium. Elgiloy, a cobalt–chromium alloy, has 
also been used for self-expanding stents. An important feature 
of nitinol is its thermal shape memory and superelasticity, 
which means nitinol is able to return to its original shape 
after severe deformation.41,42 Besides being superelastic, 
nitinol is also biocompatible. The narrow temperature range 
within which nitinol’s superelasticity is exhibited includes 
body temperature.43 Therefore, nitinol is an excellent mate-
rial for a self-expanding stent design. The ability to recover 
their original shape without clinically relevant loss of lumen 
diameter is an important distinction between nitinol and stain-
less steel stents.
Stents have to survive pulsatility, external forces, and 
bending fatigue. Balloon expandable stents are sufficiently 
rigid to prevent the native artery from stretching and expand-
ing due to the pulse pressure. The fatigue lifetime of nitinol 
far exceeds that of ordinary metals. However, extreme 
bending and crushing, which may be experienced under the 
inguinal ligament and in the popliteal or subclavian artery, 
may exceed the limitations of both balloon-expandable and 
self-expandable stents.
Nitinol stents have very low forces acting on the vessel 
wall (chronic outward force), but the force generated by a 
nitinol stent to resist compression (stiffness) increases rapidly 
with deflection; thus, a nitinol stent unloads its outward force 
when it reaches its intended diameter. Nitinol stents are able 
to adapt to the tortuous path of a vessel rather than forcing 
the vessel to straighten. Using a stiffer balloon-expandable 
stent may result in vessel straightening and concomitant 
vessel trauma.44 The most important factor causing in-stent 
restenosis is the formation of neointimal tissue hyperplasia.45 
The underlying causes of intimal hyperplasia are migration 
and proliferation of vascular smooth muscle cells provoked 
by injury, inflammation, and stretch.46
In a human cadaveric study, self-expanding stents in 
the CIA showed considerably lower radial expansion force 
than balloon-expandable stents. Moreover, precision and 
reproducibility of the achieved expansion was significantly 
lower in the self-expanding group.47 As the self-expandable 
stent begins to emerge from the constraint, there is a natural 
tendency for it to spring forward that results from several 





stent properties, including bridge design, longitudinal 
stiffness, and friction. Although this tendency in a self-
expandable stent can be reduced to a minimum nowadays, 
this potential source of inaccuracy does not exist in a 
balloon-expandable stent.43
A stent is a compromise, and there is no single stent 
that is ideal for all indications.44,48 The physical properties 
of balloon-expandable and self-expandable stents both 
exhibit superior performance in different types of arteries. 
Comparative studies on the performance of self-expandable 
and balloon-expandable stents in a clearly defined arterial 
segment are scarce (Table 1). Based on results from mainly 
in vitro studies, most physicians will prefer a balloon-
expandable stent in straight, focal, and calcified lesions 
or lesions adjacent to the aortic bifurcation; whereas, self-
expanding stents are preferred in longer and tortuous lesions 
or for contralateral approaches. High-quality clinical data to 
support this practice are lacking, but this strategy has been 
advocated in many publications.3,15,20,27–29,31,35,36,39
Limitations and future prospects
Stent fracture
The iliac artery, particularly the distal EIA prior to the ingui-
nal ligament, is exposed to flexion by bending the hip joint. 
This may lead to stent fracture. In a series of 165 patients, 
a total 305 self-expandable stents were implanted in 216 iliac 
arteries.33 Different stent types were used, according to 
the preferences of the physician. During follow-up, stent 
fracture was detected in eleven of 305 stents (3.6%). Stent 
fracture occurred in eleven of 222 nitinol stents (5.0%) but 
not in elgiloy stents. Multivariate analysis indicated stenting 
for chronic occlusion as a risk factor associated with stent 
fracture (hazard ratio: 6.09; P=0.008). No significant dif-
ferences between stents in the CIA and EIA were observed. 
Reocclusion of the stented iliac artery was only detected in 
one of eleven iliac arteries with stent fracture.49 The primary 
patency rates in iliac arteries with and without fractured stents 
at 8 years were 90% and 91%, respectively. These results are 
in contrast with the considerable risk of stent fractures in the 
femoropopliteal artery, which is associated with a higher 
in-stent stenosis and reocclusion rate.50
Covered stents
As described previously, the additional primary or selective use 
of stents improves the clinical outcome. Unfortunately, stents 
also have limitations, such as subacute occlusion and restenosis. 
Neointimal hyperplasia may grow through the struts of the stent 
and cause in-stent restenosis. A covered stent or stent graft is a 
metal stent lined with polytetrafluoroethylene (PTFE) or Dacron. 
Covered stents may overcome this limitation by introducing a 
mechanical barrier between intimal hyperplasia and the arterial 
lumen. The covered stent potentially also prevents migration of 
macrophages in the vascular wall, which are attracted by proin-
flammatory mediators secreted by the damaged vessel wall. These 
macrophages release further cyto kines,  metalloproteinases, and 
growth factors that contribute to initiating the restenotic process.51 
This concept was tested using balloon-expandable stents that 
were covered with PTFE extending for one-half of the length of 
the stent. These grafts were used to treat 12 iliac artery occlu-
sions in 12 high-risk patients. After 6 months of follow-up, the 
mean lumen diameter was significantly greater on the covered 
side than on the uncovered side.52
Table 2 Conclusions and level of evidence according to the 
Oxford Centre for Evidence Based Medicine
Conclusion Level of 
evidence
Patients treated with PTA and selective stenting for  
iliac artery stenosis have a better outcome for  
symptomatic success compared with patients treated  
with primary stenting.
1b
Primary stent placement for iliac artery occlusion  
increases technical success compared with PTA.
1b
Primary stent placement for iliac artery occlusion reduces  
major procedural complications (predominantly distal  
embolization) compared with PTA.
1b
In straight, focal, and calcified iliac artery lesions or lesions  
adjacent to the aortic bifurcation, balloon-expandable  
stents are preferred.
4
in longer and tortuous iliac artery lesions or for contralateral  
approaches, self-expanding stents are preferred.
4
Covered stents perform better for aortoiliac TASC C and D 
lesions than bare stents in long-term patency and clinical  
outcome.
1b
Note: Data from Phillips et al.70






Figure 1 Percutaneous transluminal angioplasty of the stenosis in the right common 
iliac artery and occluded external iliac artery (A) resulted in a significant residual 
stenosis and dissection, respectively (B). Additional stent placement resulted in 
technical success (C).
Abbreviations: BE, balloon-expanding; SE, self-expanding.




Self-expanding stents and aortoiliac occlusive disease
A prospective evaluation of the Hemobahn PTFE-nitinol 
self-expanding stent (WL Gore & Associates, Flagstaff, 
AZ, USA), in 61 iliac arteries and 80 femoral arteries pro-
vided primary patency rates for the iliac arteries of 98% at 
6 months and 91% at 12 months. During follow-up, one early 
occlusion (within 30 days) of a Hemobahn stent occurred in 
an iliac artery. Late occlusions (30 days to 12 months) were 
observed in an additional five iliac arteries.53
The Cordis Covered Nitinol Stent (COVENT) study 
enrolled 98 patients, who received PTFE-covered nitinol 
stents in 60 iliac arteries and 47 superficial femoral arteries. 
The primary patency rates for the iliac arteries were 94.3% at 
6 months and 90.7% at 12 months. Two iliac artery covered 
stents occluded, the first within 6 months and the second after 
8 months. In-stent recurrent stenosis developed in two other 
iliac artery-covered stents.54
Other authors have suggested that transgraft migration of 
endothelial cells may result in in-stent neointimal formation, 
which may lead to in-stent recurrent stenosis.55,56 Another 
study demonstrated significantly higher 5-year primary pat-
ency rates of 87% for predominantly self-expandable covered 
stents compared with 53% for bare metal stents (BMS) in 
patients undergoing simultaneous common femoral artery 
endarterectomy and iliac revascularization.57 These results 
are promising, but long-term data are lacking. The expla-
nation for the apparent benefit of covered stents in AIOD 
treatment is not completely clear. The decreased risk of iliac 
rupture may lead to improved dilatation with use of higher 
inflation pressure.57
Three other studies showed similar results with covered 
balloon-expandable stents.58–60 The Covered Versus Balloon-
Expandable Stent Trial (COBEST) randomly assigned 
168 iliac arteries in 125 patients to receive a covered balloon-
expandable stent or BMS. After 18 months of follow-up, cov-
ered stents and BMSs performed similarly in TASC B lesions; 
however, covered stents performed better in TASC C and D 
lesions than BMSs.61 The Dutch Iliac Stent Trial: Covered 
Balloon-Expandable versus Uncovered Balloon-Expandable 
Stents in the Common Iliac Artery (DISCOVER) is currently 
enrolling patients with a CIA occlusion or stenosis .3 cm, 
who are randomized for a balloon-expandable covered stent 
or BMS.62
Future perspectives
A new self-expanding interwoven nitinol stent has shown 
encouraging results in the popliteal artery.63 This novel Supera 
stent (Abbott Vascular, Santa Clara, CA, USA), consists of 
woven nitinol wires braided in a tubular mesh configuration. 
This specific configuration results in a stent that is flexible, 
compliant, and self-expanding and that has a very high radial 
resistive force. This device may perform very well in com-
plex iliac lesions; however, the largest currently available 
diameter is 8 mm.
Several promising stenting techniques are already 
available for noniliac arteries. In cardiology, the use of 
drug-eluting stents (DES) shows beneficial results. These 
coronary devices have been shown to be superior to BMS 
in tibial arteries too.64,65 A novel nitinol paclitaxel-eluting 
stent is available for the femoropopliteal artery. In a large 
randomized controlled trial, DESs showed superior 12-month 
event-free survival and primary patency rates compared with 
PTA. In the PTA group, 120 patients had acute PTA failure 
and underwent secondary random assignment to provisional 
DES or BMS. The provisional DES group exhibited superior 
12-month primary patency and clinical benefit compared 
with the provisional BMS group.66 This particular device 
is not yet available for the iliac arteries, but another self-
expanding everolimus-eluting stent has been analyzed in an 
animal model. The iliac arteries of 24 Yucatan mini-swine 
were treated with the 8×28 mm nitinol everolimus-eluting 
stent. Bare nitinol stents were implanted in the contralateral 
iliac arteries to serve as controls. During the first 6 months, 
local arterial stent-mediated delivery of everolimus inhibited 
the formation of neointimal hyperplasia.67
A drug-eluting bioresorbable vascular scaffold seems to 
be very promising in coronary arteries.68,69 This technology 
is currently being investigated in femoropopliteal lesions and 
may become available for the iliac artery in the future.
Conclusion
PTA and stenting is the preferred treatment modality in 
patients with AIOD and has been associated with satisfac-
tory long-term results, even in challenging lesions. Primary 
stenting is indicated in iliac artery occlusions, while in iliac 
artery stenoses, selective stenting is preferred. Unfortunately, 
detailed information about the performance of different stent 
types in clearly defined iliac artery segments is limited. 
The unique properties of self-expanding stents make them 
particularly suitable for the treatment of long, tortuous, and 
mobile arteries, like the EIA. The most important limitation 
is in-stent restenosis resulting from neointimal hyperplasia. 
Use of covered or DESs seems promising, but more evidence 
is needed to finally prove these concepts (Table 2).
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